

# MEDICAMEN Biotech Limited



Regd. & Corp. Office:  
1506, Chiranjiv Tower,  
43, Nehru Place,  
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),  
E-mail: info@medicamen.com  
Web: www.medicamen.com  
CIN No.: L74899DL1993PLC056594

Ref: STEX/Results/Published-2023-24

Date: 09.08.2023

To

<b>BSE Limited</b> <b>25th Floor, Phiroze Jeejebhoy Towers</b> <b>Dalal Street, Mumbai 400 001</b>  <b>BSE Code-531146</b>	<b>National Stock Exchange of India Limited</b> <b>Exchange Plaza, C-1,</b> <b>Block - G Bandra Kurla</b> <b>Complex Bandra (East)</b> <b>Mumbai – 400 051</b>  <b>NSE Code: MEDICAMEQ</b>
--	--

**Company Number: 531146**

**Sub. : Copy of Publication for Un- Audited Financial Results for the quarter ended June 30, 2023**

Dear Sir,

Pursuant to regulation 30 & 47 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015 ("the Regulations"), please find enclosed newspaper cutting with regard to the publication of extract of Un-Audited Financial Results of the Company for the quarter ended on June 30, 2023 approved by the Board of Directors at their Meeting held on 08.08.2023.

The copy of the results published in the Financial Express and Jansatta dated August 09, 2023 is enclosed.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking You,

Yours truly,

**For Medicamen Biotech Limited**

**Parul Choudhary**  
**Company Secretary**  
**ACS-44157**

Encl: As above.

**LEAD FINANCIAL SERVICES**

Regd. Office: 101, Sita Ram Mansion, 718/21, Joshi  
CIN L74140DL1993PLC

Extract of Unaudited Financial Results for the

S. No.	Particulars	30.06.23 (Review)
1.	Total income from operations	8.1
2.	Net Profit/ (Loss) for the period (before tax and exceptional items)	3.1
3.	Net Profit/ (Loss) for the period before tax (after exceptional items)	3.1
4.	Net Profit/ (Loss) for the period after tax (after exceptional items)	2.1
5.	Total Comprehensive Income for the period (Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	3.1
6.	Paid-up Equity Share Capital (Face Value of Rs. 10/- each)	330.0
7.	Other Equity	0.0
8.	Earnings Per Share (of Rs. 10/- each) (Not annualised) Basic: Diluted:	0.0 0.0

Note: The above is an extract of the detailed format of Quarterly Results under Regulation 33 of the SEBI (Listing Obligations and Disclosures) Regulations, 2015. The full format of the Quarterly results is available on the stock exchange website www.leadfinancialservices.in.

New Delhi  
August 8, 2023

**KERALA WATER AUTHORITY e-Tender Notice**

Tender No: 101-103/2023-24/PHC/KNR(Re-tender)  
Jal Jeevan Mission-Kannur-Kasaragod-Maluru Panchayath-Zone II- WSS to Mattannur, Irity and adjoining Panchayaths-WSS to Kumbala and Mangalpady Panchayath-Package II & III-Construction of OHSRs, Distribution and providing FHICs EMD: Rs. 200000-500000  
Tender fee : Rs. 13010-19518 Last Date for submitting Tender: 18-08-2023 03:00:pm  
Phone: 04972705902 Website: [www.kwa.kerala.gov.in](http://www.kwa.kerala.gov.in) [www.etenders.kerala.gov.in](http://www.etenders.kerala.gov.in)

Superintending Engineer  
PH Circle  
Kannur

KWA-JB-GL-6-979-2023-24



**MEDICAMEN BIOTECH LTD.**

Regd. Office: 1506, Chiranjiv Tower 43, Nehru Place, New Delhi-110019  
CIN: L74899DL 1993PLC056594 E-mail: [cs@medicamen.com](mailto:cs@medicamen.com), [www.medicamen.com](http://www.medicamen.com)

Un-audited standalone and consolidated financial results for the quarter ended as on 30th June 2023

Rupees in Lacs (Except per Share data)

Sl. No.	Particulars	Standalone				Consolidated			
		Three months period ended		Year ended	Three months period ended		Year ended		
		Un-audited 30.06.2023	Audited 31.03.2023		Un-audited 30.06.2022	Audited 31.03.2023			
1	Total income from operations (net)	4088.26	3749.48	3405.03	14034.62	4232.23	3901.19	3405.03	14332.96
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	515.33	464.70	432.50	1733.28	468.33	435.55	432.50	1704.50
3	Net Profit/ (Loss) for the period before tax (after exceptional and/ or Extraordinary items)	515.33	464.70	432.50	1733.28	468.33	435.55	432.50	1704.50
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	441.70	404.60	358.56	1500.20	394.70	376.87	358.56	1472.85
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	441.70	404.60	358.56	1500.20	394.70	376.87	358.56	1472.85
6	Equity Share Capital	1265.11	1265.11	1221.66	1265.11	1265.11	1265.11	1221.66	1265.11
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)								
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operation)								
	Basic:	3.49	3.25	2.94	12.04	3.12	3.03	2.94	11.82
	Diluted:	3.49	3.25	2.94	12.04	3.12	3.03	2.94	11.82

**Notes:**

- The Un-audited financial results for the quarter ended have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 8 August 2023
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - Earning per Share
- The results are not comparable on quarterly or yearly basis as company is regularly incurring capex and filling dossiers with regulatory authorities.
- Limited review report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For Medicamen Biotech Limited  
Sd/  
Rahul Bishnoi  
Chairman

Place: New Delhi  
Date: 08.08.2023

**INTERNATIONAL LIMITED**

CIN: L24100UP1994PLC022559  
SGM Plaza, Arya Nagar, Kanpur UP 208002  
Tel. No.: 011-23852666  
E-mail: [rgc.secretarial@rediffmail.com](mailto:rgc.secretarial@rediffmail.com)

**FINANCIAL RESULTS FOR QUARTER ENDED ON 30.06.2023**

STANDALONE			CONSOLIDATED	
Quarter ended	Quarter ended	Financial Year ended	Quarter ended	Quarter ended
30.06.2023	30.06.2022	31.03.2023	30.06.2023	31.03.2022
Audited	Unaudited	Audited	Unaudited	Audited
534	(0.377)	(22.910)	(2.280)	(61.506)
534	(0.377)	(22.910)	(2.280)	(61.506)
534	(0.377)	(22.910)	(2.280)	(61.506)
534	(0.377)	(22.910)	(2.280)	(61.506)
0.002	50.002	50.002	50.002	50.002
-	-	439.786	-	-
1.471	(0.008)	(0.458)	(0.046)	(1.230)

Consolidated Financial Results for Quarter ended on 30th June 2023 (Disclosure Requirement) Regulations, 2015. The full format of the Quarterly results is available on the Stock Exchange Website ([www.sebi.gov.in](http://www.sebi.gov.in))

For Raghunath

**RTCL LIMITED**

CIN No.: L16003UP1994PLC016225  
Registered Office: 8/226, Second Floor, SGM Plaza, Arya Nagar, Kanpur UP 208002  
Tel. No.: 011-23852583, Fax No.: 011-23852666  
Website: [www.raghunathintlimited.in](http://www.raghunathintlimited.in), E-mail: [rgc.secretarial@rediffmail.com](mailto:rgc.secretarial@rediffmail.com)

OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR QUARTER ENDED ON 30.06.2023

## CSB Bank PUBLIC NOTICE ON AUCTION OF PLEDGED GOLD ORNAMENTS

The borrower/s in specific and interested bidders, in general, are hereby informed that on account of non-repayment of the Bank's dues by the borrowers as under despite the payment notice and recall/auction notice issued by the Bank, the gold ornaments pledged with the bank as security by the respective borrowers for the loans availed by them will be sold in public auction on "as is where is" and "non-recourse" basis through e-auction portal <http://csbgold.auctiontiger.net> on 16th August 2023 at 10.30 AM. The auction may be adjourned to any other later date at the discretion of the bank upon publication of the same in the Bank's notice board. The borrowers are hereby further informed that the gold ornaments will be disposed of by private sale if the public auction is not successful and if there is a further balance to be recovered thereafter, legal action will be initiated against the borrower/s for recovery of the balance amounts due to the bank.

S.No.	Branch Name	Account Name	Client ID	No. of Acc.	Bal. Outstanding as on 07-08-2023	Weight (grams)
1	CHANDIGARH	GEETIKA PATHAK	2827947	1	1051376.65	309
2	CHANDIGARH	RAMA SHARMA	2799111	1	309512	88.9
3	CHANDIGARH	SAMRIDHI	4190968	1	123317.45	46.5
4	CHANDIGARH	SANJEEV CHAUHAN	4347227	1	121725.55	45
5	CHANDIGARH	VARUN GUPTA	3831701	1	252458.08	59.8

For more details/account wise information borrowers/interested bidders may contact respective branches and for participating in the auction, please visit/login to the e-auction portal <http://csbgold.auctiontiger.net>

Authorised Officer  
CSB Bank

CHANDIGARH | 9th August 2023



रेलटेल  
(भारत सरकार का उपक्रम)  
सीआइएल नंबर: L64202D12000G01107905

निविदा संख्या: रेलटेल/टेंडर/ओटी/ईआर/एचएच/2023-24/1477-1483, दिनांक: 08.08.2023

रेलटेल पूर्वी क्षेत्र "रेलटेल कॉर्पोरेशन ऑफ इंडिया लिमिटेड, पूर्वी क्षेत्र के लिए छत्तीसगढ़ और मध्य प्रदेश राज्यों में साठम ईस्टर्न कोलमोल्ब्स लिमिटेड के क्षेत्र में जीवी/आरटी टार्वरों की आपूर्ति, स्थापना और कमीशनिंग सहित लास्ट माइल आरएफ लिंक को क्रिये पर सेना के कार्यों के लिए पात्र बोलीदाताओं से ई-बोलियों आमंत्रित करता है।

विस्तृत निविदा सूचना/ निविदा दस्तावेज [www.railtelindia.com](http://www.railtelindia.com), <https://eprocure.gov.in> और <https://railtel.enivida.com> पर उपलब्ध है। भविष्य के सभी परिशिष्ट/सुद्धिपत्र आदि को रेलटेल वेबसाइट, सीपीपी पोर्टल और ई-निविदा पोर्टल पर अपलोड किया जाएगा। बोलीदाताओं को केवल ई-निविदा पोर्टल पर अपनी बोली जमा करनी होगी।



## MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower 43, Nehru Place, New Delhi-110019  
CIN: L74899DL1993PLC056594 E-mail: [cs@medicamen.com](mailto:cs@medicamen.com), [www.medicamen.com](http://www.medicamen.com)

Un-audited standalone and consolidated financial results for the quarter ended as on 30th June 2023

Rupees in Lacs (Except per Share data)

Sl. No.	Particulars	Standaone				Consolidated			
		Three months period ended		Year ended		Three months period ended		Year ended	
		Un-audited 30.06.2023	Audited 31.03.2023	Un-audited 30.06.2022	Audited 31.03.2023	Un-audited 30.06.2023	Audited 31.03.2023	Un-audited 30.06.2022	Audited 31.03.2023
1	Total income from operations (net)	4088.26	3749.48	3405.03	14034.62	4232.23	3901.19	3405.03	14332.96
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	515.33	464.70	432.50	1733.28	468.33	435.55	432.50	1704.50
3	Net Profit/ (Loss) for the period before tax (after exceptional and/ or Extraordinary items)	515.33	464.70	432.50	1733.28	468.33	435.55	432.50	1704.50
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	441.70	404.60	358.56	1500.20	394.70	376.87	358.56	1472.85
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	441.70	404.60	358.56	1500.20	394.70	376.87	358.56	1472.85
6	Equity Share Capital	1265.11	1265.11	1221.66	1265.11	1265.11	1265.11	1221.66	1265.11
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)								
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operation)								
	Basic:	3.49	3.25	2.94	12.04	3.12	3.03	2.94	11.82
	Diluted:	3.49	3.25	2.94	12.04	3.12	3.03	2.94	11.82

### Notes:

- The Un-audited financial results for the quarter ended have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 8 August 2023
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - Earning per Share
- The results are not comparable on quarterly or yearly basis as company is regularly incurring capex and filling dossiers with regulatory authorities.
- Limited review report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For Medicamen Biotech Limited  
Sd/-  
Rahul Bishnoi  
Chairman

Place: New Delhi  
Date: 08.08.2023